ā¢
CG
CGTX
Cognition Therapeutics, Inc. Common Stock
polygonBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
123.58M
Volume
600.49K
52W High
$3.83
52W Low
$0.22
Open
$1.40
Prev Close
$1.40
Day Range
1.39 - 1.44
About Cognition Therapeutics, Inc. Common Stock
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Latest News
James M. OāBrien Appointed Chief Financial Officer at Mesoblast
GlobeNewswire Inc.ā¢Nov 17
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025
The Motley Foolā¢Sep 3
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
GlobeNewswire Inc.ā¢Sep 2
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
GlobeNewswire Inc.ā¢Aug 28
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update
GlobeNewswire Inc.ā¢Mar 20
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
GlobeNewswire Inc.ā¢Oct 29
Catalyst Accelerator Ogden Selects 11 Companies for Fall 2024 Cohort in Partnership with the Department of the Air Force Digital Transformation Office
GlobeNewswire Inc.ā¢Aug 23
Results from Cognition Therapeuticsā Phase 2 SHINE Study of CT1812Ā in Mild-to-Moderate Alzheimerās Disease Accepted for Presentation at AAIC
GlobeNewswire Inc.ā¢Jul 2